Robert J. Dempsey
CEO & Executive DirectorMr. Robert J. Dempsey M.B.A., also known as Bob, is Independent Chairman of the Board of Azalea Vision BV. He was an Interim Chief Executive Officer of Ashvattha Therapeutics, Inc. from October 14, 2025 to 2026. Mr. Dempsey is CEO & Executive Director of OKYO Pharma Limited from January 5, 2026. His philanthropic time is spent as founder and board director of The Holland Foundation for Sight Restoration. He served as an Executive Chairman at TearSolutions, Inc. since June 2024 until August 2026. He was Director of TearSolutions, Inc. from November 2023 until august 2026. He served as Chief Executive Officer at AsclepiX Therapeutics, LLC. He serves as Director at Glauconix Biosciences, Inc. (Humonix Biosciences, Inc.). since October 2019. He was Director of Neurotech Pharmaceuticals, Inc. He is a Director of iVeena Delivery Systems, Inc., served as its Chairman of the Board until 2026 and serves as Co-Chairman of the Board from 2026 and serves as its Interim Chief Executive Officer since 2025. Mr. Dempsey joined Shire in 2014 and was Group Vice President and Head of the Global Ophthalmology Franchise. He led Shire’s Ophthalmology Franchise in the US. He was instrumental in building and launching the Franchise and has extensive leadership experience in sales, marketing, medical affairs and business development. He has diverse experience in the eye care industry. In August of 2018, he joined the Board of SciFluor a subsidiary of Allied Minds. In addition, he serves on the Boards of the International Council of Ophthalmology Foundation, St. Elizabeth’s Restoration of Sight Foundation and is a frequent panel Member at the Ophthalmology Innovation Summit. He served as the Chief Executive Director of TearClear Corp. since April 2020 until March 2021. He served as Director at OcuTerra Therapeutics, Inc. (formerly known as SciFluor Life Sciences, Inc.) until December 2021. He has extensive knowledge of the Pharmaceutical Industry along with focus in Ophthalmology to the Board of SciFluor. He has been instrumental in building and launching franchises and has extensive leadership experience in sales, marketing, medical affairs and business development at major Eye Care organizations including Shire where he is leading the Global Ophthalmology Franchise. He has held numerous leadership positions at Bausch + Lomb, Inspire and Allergan and is recognized for his knowledge and experience in Ophthalmology, his strategic relationships with industry leaders and professionals in Eye Care. He holds a master’s in business administration and a Bachelor of Science from Northeastern University in Boston, Massachusetts.
Positions
- Company NameOKYO Pharma LimitedStock CodeOKYOPositionCEO & Executive DirectorColleagues
- GMGabriele Marco Antonio CerroneNon-Executive Chairman
- KSKeeren ShahChief Financial Officer
- RPRajkumar PatilChief Scientific Officer
- GSGary S. JacobChief Development Officer & Director
- FMFlavio MantelliChief Medical Officer
- WJWilly Jules SimonSenior Independent Non-Executive Director
- JPJohn Patrick BrancaccioIndependent Non-Executive Director
